liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Tamoxifen therapy benefit for patients with 70-gene signature high and low risk
University of Calif San Francisco, CA 94115 USA.
University of Calif San Francisco, CA 94115 USA; Buck Institute Research Aging, CA 94945 USA.
Karolinska Institute, Sweden.
Buck Institute Research Aging, USA; University of Calif San Francisco,USA.
Vise andre og tillknytning
2017 (engelsk)Inngår i: Breast Cancer Research and Treatment, ISSN 0167-6806, E-ISSN 1573-7217, Vol. 166, nr 2, s. 593-601Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Breast cancer molecular prognostic tools that predict recurrence risk have mainly been established on endocrine-treated patients and thus are not optimal for the evaluation of benefit from endocrine therapy. The Stockholm tamoxifen (STO-3) trial which randomized postmenopausal node-negative patients to 2-year tamoxifen (followed by an optional randomization for an additional 3-year tamoxifen vs nil), versus no adjuvant treatment, provides a unique opportunity to evaluate long-term 20-year benefit of endocrine therapy within prognostic risk classes of the 70-gene prognosis signature that was developed on adjuvantly untreated patients. We assessed by Kaplan-Meier analysis 20-year breast cancer-specific survival (BCSS) and 10-year distant metastasis-free survival (DMFS) for 538 estrogen receptor (ER)-positive, STO-3 trial patients with retrospectively ascertained 70-gene prognosis classification. Multivariable analysis of long-term (20 years) BCSS by STO-3 trial arm in the 70-gene high-risk and low-risk subgroups was performed using Cox proportional hazard modeling adjusting for classical patient and tumor characteristics. Tamoxifen-treated, 70-gene low- and high-risk patients had 20-year BCSS of 90 and 83%, as compared to 80 and 65% for untreated patients, respectively (log-rank p amp;lt; 0.0001). Notably, there is equivalent tamoxifen benefit in both high (HR 0.42 (0.21-0.86), p = 0.018) and low (HR 0.46 (0.25-0.85), p = 0.013) 70-gene risk categories even after adjusting for clinico-pathological factors for BCSS. Limited tamoxifen exposure as given in the STO-3 trial provides persistent benefit for 10-15 years after diagnosis in a time-varying analysis. 10-year DMFS was 93 and 85% for low- and high-risk tamoxifen-treated, versus 83 and 70% for low- and high-risk untreated patients, respectively (log-rank p amp;lt; 0.0001). Patients with ER-positive breast cancer, regardless of high or low 70-gene risk classification, receive significant survival benefit lasting over 10 years from adjuvant tamoxifen therapy, even when given for a relatively short duration.

sted, utgiver, år, opplag, sider
SPRINGER , 2017. Vol. 166, nr 2, s. 593-601
Emneord [en]
70-gene signature; Tamoxifen benefit; Endocrine therapy; Breast cancer; Long-term survival
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-143077DOI: 10.1007/s10549-017-4428-9ISI: 000414472400025PubMedID: 28776283OAI: oai:DiVA.org:liu-143077DiVA, id: diva2:1159445
Merknad

Funding Agencies|California Breast Cancer Research Program BCRP award [180B-0065]; Breast Cancer Research Foundation [BCRF]; Swedish Research Council [521-2014-2057]; FORTE [2014-1962]; Stiftelsen Gosta Miltons Donationsfond [The Gosta Milton Donation Fund]; Cancerforeningen i Stockholm [Stockholm Cancer Society]

Tilgjengelig fra: 2017-11-22 Laget: 2017-11-22 Sist oppdatert: 2018-01-05

Open Access i DiVA

fulltext(419 kB)120 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 419 kBChecksum SHA-512
79ff11122ce4eca7e747a59358df5457ed5e39f010e777c52ecbb50f2a99a22f00e400b9c15996ba2a35b177674a97b94fb087b6b29687cf235044aa7f243711
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Søk i DiVA

Av forfatter/redaktør
Nordenskjöld, BoStål, Olle
Av organisasjonen
I samme tidsskrift
Breast Cancer Research and Treatment

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 120 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 139 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf